Takeda Discontinues Involvement In Matuzumab After Phase II Failure
This article was originally published in PharmAsia News
Takeda will no longer jointly pursue development of cancer monoclonal antibody matuzumab because the epidermal growth factor receptor antagonist failed to meet primary endpoints in a Phase II trial, the Osaka, Japan-based company announced Feb. 18
You may also be interested in...
ImClone and Bristol-Myers Squibb are attempting to make Erbitux (cetuximab) the first EGFR receptor-inhibiting monoclonal antibody to be available in Japan under a co-development and co-commercialization agreement with Merck KGaA announced Oct. 17
Merck Serono is reconsidering development of its monoclonal antibody matuzumab for the treatment of metastatic colorectal cancer after a Phase II study failed to meet its efficacy endpoint, the company announced Aug. 29
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).